Is Elevai Labs, Inc. Common Stock (ELAB) overvalued? · rev $1.7M
Elevai Labs, Inc. Common Stock (ELAB) is a biotechnology company listed on NASDAQ.
This page asks whether Elevai Labs, Inc. Common Stock (ELAB) looks expensive on cached numbers — not a short thesis.
Latest reported ELAB revenue for 2023-12-31 was $1.7M. Net income was -$4.3M. Revenue was up 123.5% from 2022-12-31 to 2023-12-31. ELAB currently screens at market cap $6.5M.
ELAB currently screens at market cap $6.5M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ELAB 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ELAB stock page for the full model, not this heading.
Not investment advice.